RDIF and ChemRar exceed target production of Avifavir
The Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, and affiliate ChemRar Group produced the first 100,000 courses of the Russian coronavirus drug Avifavir (favipiravir) in June, significantly exceeding initially planned production levels of 60,000 courses, the partners announced.
On May 29, 2020, Avifavir received a registration certificate from Russia's Ministry of Health and became the first favipiravir-based drug in the world approved for the treatment of COVID-19.
In June, the drug was delivered across Russia's 35 regions and to the Republic of Belarus. Agreement has also been reached for deliveries of Avifavir to Kazakhstan in the near future. In total, more than 100,000 courses will be produced in July.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze